Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1

被引:40
作者
Kawamura, Akane [1 ]
Westwood, Isaac [1 ]
Wakefield, Larissa [1 ]
Long, Hilary [1 ]
Zhang, Naixia [2 ]
Walters, Kylie [2 ]
Redfield, Christina [3 ]
Sim, Edith [1 ]
机构
[1] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England
[2] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA
[3] Univ Oxford, Dept Biochem, Oxford OX1 3QU, England
基金
英国惠康基金;
关键词
arylamine N-acetyltransferase/NAT; enzyme inhibition; selective estrogen receptor; modulator/SERM; steroid; xenobiotic; breast cancer;
D O I
10.1016/j.bcp.2007.12.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is increasing evidence that human arylamine N-acetyltransferase type 1 (NAT1, EC 2.3.1.5), although first identified as a homologue of a drug-metabolising enzyme, appears to be a marker in human oestrogen receptor positive breast cancer. Mouse Nat2 is the mouse equivalent of human NAT1. The development of mouse models of breast cancer is important, and it is essential to explore the biological role of mouse Nat2. We have therefore produced mouse Nat2 as a recombinant protein and have investigated its substrate specificity profile in comparison with human NAT1. In addition, we have tested the effects of inhibitors on mouse Nat2, including compounds which are endogenous and exogenous steroids. We show that tamoxifen, genistein and diethylstilbestrol inhibit mouse Nat2. The steroid analogue, bisphenol A, also inhibits mouse Nat2 enzymic activity and is shown by NMR spectroscopy, through shifts in proton peaks, to bind close to the active site. A three-dimensional structure for human NAT1 has recently been released, and we have used this crystal structure to generate a model of the mouse Nat2 structure. We propose that a conformational change in the structure is required in order for ligands to bind to the active site of the protein. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:1550 / 1560
页数:11
相关论文
共 49 条
[1]  
Adam PJ, 2003, MOL CANCER RES, V1, P826
[2]   mILC-ing the mouse mammary gland: A model for invasive lobular carcinoma [J].
Alvarez, James V. ;
Perez, Denise ;
Chodosh, Lewis A. .
CANCER CELL, 2006, 10 (05) :347-349
[3]   Estrogen receptors as therapeutic targets in breast cancer [J].
Ariazi, Eric A. ;
Ariazi, Jennifer L. ;
Cordera, Fernando ;
Jordan, V. Craig .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (03) :181-202
[4]   An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases [J].
Brooke, EW ;
Davies, SG ;
Mulvaney, AW ;
Pompeo, F ;
Sim, E ;
Vickers, RJ .
BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (07) :1227-1234
[5]   Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene [J].
Cornish, VA ;
Pinter, K ;
Boukouvala, S ;
Johnson, N ;
Labrousse, C ;
Payton, M ;
Priddle, H ;
Smith, AJH ;
Sim, E .
PHARMACOGENOMICS JOURNAL, 2003, 3 (03) :169-177
[6]  
Estrada-Rodgers L, 1998, DRUG METAB DISPOS, V26, P502
[7]   Divergence of cofactor recognition across evolution:: Coenzyme a binding in a prokaryotic arylamine N-acetyltransferase [J].
Fullam, Elizabeth ;
Westwood, Isaac M. ;
Anderton, Matthew C. ;
Lowe, Edward D. ;
Sim, Edith ;
Noble, Martin E. M. .
JOURNAL OF MOLECULAR BIOLOGY, 2008, 375 (01) :178-191
[8]   Weight of the evidence evaluation of low-dose reproductive and developmental effects of bisphenol A [J].
Gray, GM ;
Cohen, JT ;
Cunha, G ;
Hughes, C ;
McConnell, EE ;
Rhomberg, L ;
Sipes, IG ;
Mattison, D .
HUMAN AND ECOLOGICAL RISK ASSESSMENT, 2004, 10 (05) :875-921
[9]  
Gruvberger S, 2001, CANCER RES, V61, P5979
[10]   Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer [J].
Hess, Kenneth R. ;
Anderson, Keith ;
Symmans, W. Fraser ;
Valero, Vicente ;
Ibrahim, Nuhad ;
Mejia, Jaime A. ;
Booser, Daniel ;
Theriault, Richard L. ;
Buzdar, Aman U. ;
Dempsey, Peter J. ;
Rouzier, Roman ;
Sneige, Nour ;
Ross, Jeffrey S. ;
Vidaurre, Tatiana ;
Gomez, Henry L. ;
Hortobagyi, Gabriel N. ;
Pusztai, Lajos .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4236-4244